Related Experiment Video
Updated: Nov 29, 2025

Barnes Maze Testing Strategies with Small and Large Rodent Models
Published on: February 26, 2014
RAGE signaling is required for AMPA receptor dysfunction in the hippocampus of hyperglycemic mice
Zeinab Momeni1, Maricris Bautista2, Joseph Neapetung1
1Department of Anatomy, Physiology, and Pharmacology (APP), 107 Wiggins Road, University of Saskatchewan, Saskatoon, S7N 5E5, SK, Canada.
Abstract:
Diabetes in humans has been associated for a long time with cognitive dysfunction. In rodent animal models, cognitive dysfunction can manifest as impaired hippocampal synaptic plasticity. Particular attention has been concentrated on the receptor for advanced glycation end products (RAGE), which is implicated in multiple diabetic complications involving the development of vascular and peripheral nerve abnormalities. In this study, we hypothesize that RAGE signaling alters glutamate receptor function and expression, impairing synaptic transmission in the hippocampus. Using preparations of hippocampal slices from male mice, we show a RAGE-dependent decrease in long-term potentiation (LTP) and an increase in paired-pulse facilitation (PPF) following streptozotocin (STZ)-induced diabetes. Consistently, in hippocampal cultures from male and female neonatal mice, high glucose caused a RAGE-dependent reduction of AMPA- but not NMDA-evoked currents, and an increase in cytosolic reactive oxygen species (ROS). Consistently, when cultures were co-treated with high glucose and the RAGE antagonist FPS-ZM1, AMPA-evoked currents were unchanged. Hippocampi from STZ-induced hyperglycemic wild type (WT) mice showed increased RAGE expression concomitant with a decrease of both expression and phosphorylation (Ser 831 and 845) of the AMPA GluA1 subunit. We found these changes correlated to activation of the MAPK pathway, consistent with decreased pJNK/JNK ratio and the JNK kinase, pMEK7. As no changes in expression or phosphorylation of regulatory proteins were observed in hippocampi from STZ-induced hyperglycemic RAGE-KO mice, we report a RAGE-dependent impairment in the hippocampi of hyperglycemic WT mice, with reduced AMPA receptor expression/function and LTP deficits.
Insights
Diabetes impairs brain function by affecting synaptic plasticity in the hippocampus. Receptor for advanced glycation end products (RAGE) signaling in diabetes reduces AMPA receptor function, leading to cognitive deficits.
Area of Science:
- Neuroscience
- Endocrinology
- Diabetology
Background:
- Diabetes mellitus is linked to cognitive dysfunction, potentially involving hippocampal synaptic plasticity.
- Receptor for advanced glycation end products (RAGE) is implicated in diabetic complications, including nerve and vascular issues.
Purpose of the Study:
- To investigate the role of RAGE signaling in diabetes-induced alterations of hippocampal synaptic transmission and glutamate receptor function.
- To determine if RAGE antagonism can prevent these diabetes-related synaptic deficits.
Main Methods:
- Utilized streptozotocin (STZ)-induced diabetes mouse models and primary hippocampal cultures.
- Measured long-term potentiation (LTP) and paired-pulse facilitation (PPF) in hippocampal slices.
- Assessed AMPA and NMDA receptor-mediated currents, reactive oxygen species (ROS), and protein expression (RAGE, GluA1, MAPK pathway) in hippocampal tissues and cultures.
Main Results:
- STZ-induced diabetes in wild-type (WT) mice showed RAGE-dependent decreases in LTP and increases in PPF.
- High glucose in hippocampal cultures reduced AMPA-evoked currents and increased ROS in a RAGE-dependent manner.
- RAGE antagonism (FPS-ZM1) prevented high glucose-induced AMPA current reduction.
- Hyperglycemic WT mice exhibited increased RAGE expression and decreased AMPA GluA1 subunit expression/phosphorylation, linked to MAPK pathway activation.
Conclusions:
- RAGE signaling mediates diabetes-induced impairment of hippocampal synaptic transmission.
- Reduced AMPA receptor function and expression, along with LTP deficits, contribute to cognitive dysfunction in diabetes.
- Targeting RAGE may offer a therapeutic strategy for diabetic cognitive impairment.
Related Concept Videos
Hypoglycemia and Glucagon
Insulin: The Receptor and Signaling Pathways

